Table 1.
Patient characteristics
| Characteristics |
Training cohort No. (%) |
Validation cohort No. (%) |
P value |
|---|---|---|---|
| Sex (male/female) | 31/33 | 44/42 | 0.512 |
| Age (median y, range) | 74 (33‐86) | 71 (24‐90) | 0.019 |
| ECOG Performance status | <0.01 | ||
| 0, 1 | 45 (70) | 81 (94) | |
| ≥2 | 19 (30) | 5 (6) | |
| Stage | <0.01 | ||
| I, II | 12 (19) | 54 (63) | |
| III | 13 (20) | 11 (13) | |
| IV | 39 (61) | 21 (24) | |
| Extranodal sites | 0.281 | ||
| 0 | 33 (34) | 60 (70) | |
| ≥1 | 42 (66) | 26 (30) | |
| Bone marrow involvement | 0.541 | ||
| Yes | 11 (17) | 10 (12) | |
| No | 53 (83) | 76 (88) | |
| B symptoms | 0.330 | ||
| Yes | 29 (58) | 12 (14) | |
| No | 35 (42) | 74 (86) | |
| LDH | 0.285 | ||
| ≤Normal | 21 (33) | 45 (52) | |
| ≥Normal | 43 (67) | 41 (48) | |
| sIL‐2R | 0.409 | ||
| Median (range) | 1735 (243‐43 700) U/mL | 1274 (200‐39 798) U/mL | |
| <1300 | 27 (42) | 40 (47) | |
| ≥1300 | 37 (58) | 46 (53) | |
| TMTV | 0.411 | ||
| Median (range) | 236.32 (76.62‐677.09) cm3 | 167.2305 (4.61‐5445.50) cm3 | |
| <150 | 26 (41) | 44 (51) | |
| ≥150 | 38 (59) | 42 (49) | |
| NCCN‐IPI | 0.014 | ||
| Low, Low‐int | 15 (24) | 47 (55) | |
| High‐int | 20 (31) | 33 (38) | |
| High | 29 (45) | 6 (7) | |
| Treatment | <0.01 | ||
| R‐CHOP | 27(42) | 81(94) | |
| R‐THP‐COP | 36(56) | 5(6) | |
| R‐CVP | 1(2) | 0(0) | |
| Outcome | |||
| CR | 42 (66) | 69 (80) | 0.0594 |
| PR | 7(11) | 2(2) | 0.0378 |
| Residual disease | 18 (28) | 18 (21) | 0.338 |
| Relapse | 16 (25) | 14 (16) | 0.218 |
| Death from disease | 12 (19) | 5 (6) | 0.0184 |
| Treatment‐related death | 11 (17) | 8 (9) | 0.214 |
| Death from other reasons | 5 (8) | 2 (2) | 0.134 |
CR, complete remission; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; NCCN‐IPI, National Comprehensive Cancer Network‐International Prognostic Index; PR, partial remission; residual disease includes the patient with PR, stable disease, and progressive disease.; R‐CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R‐CVP, rituximab, cyclophosphamide, vincristine, and prednisolone; R‐THP‐COP, rituximab, therarubicin, cyclophosphamide, vincristine, and prednisone; sIL‐2R, soluble interleukin‐2 receptor; TMTV, total metabolic tumor volume.